List of Selected Clients

Agrivida is an agricultural biotechnology company focused on creating renewable, biomass-based alternative fuels and raw materials. They are developing corn varieties that are optimized for producing ethanol from corn stover, otherwise known as "cellulosic" ethanol. Corn stover is, collectively, the leaves, stalks, and husks of corn and is an inexpensive route to increase yields of ethanol per bushel of corn.

AllerQuest was setup specifically to further develop and produce PRE -PEN and MDM , agents for testing penicillin allergy available to the medical community.

Conversion Energy Enterprises (CEE) specializes in design and development of medical systems utilizing advanced concepts in electronic lasers and biomaterials with a focus on laser assisted joining of tissue. CEE develops and provides preclinical systems and tissue adhesive technology. Their focus is on hernia repair and ophthalmic applications. CEE is working on collaboration with Michael Pikal, an UConn Department of Pharmacy professor.

Catelectric, Inc. (CE) is a private early stage company with a mission to develop products for the clean energy markets (fuel cells and pollution control) based on its proprietary platform catalytic process technology. The CE processes provide an effective set of methods for controlling the type and number of catalytic sites (areas where the chemical reactions occur). The result is a substantial enhancement of the yield of a catalytic system. The CE processes achieve the desired degree of manipulation of the properties of catalytic interfaces/sites through the modification of some of their physical characteristics at nanometer level. Catelectric collaborates with Dr. Steve Suib, distinguished faculty of the UConn chemistry department, for their research.

Evergen Biotechnology was founded by UConn Professor Jerry Yang, who is globally recognized for his contributions in the areas of agricultural biotechnology and embryology. Evergen primarily develops and produces products and services to boost both the quality and quantity of dairy calves and their potential milk productivity. Evergen technologies include in vitro fertilization, transgenic animal production, cloning and sex sorting. Evergen expects its technologies to have a major impact on milk production in undeveloped countries like China where there is a critical shortage of milk.

Lifepharms is researching natural products for medicinal and agricultural uses, including anticancer and pox virus medications. LifePharms, Inc. is a biotechnology company that is focusing on discovering novel lead compounds from natural products for both medicinal and agricultural uses.  Natural products and their derivatives are the source of many marketed products.  It is estimated that up to 40% of all drugs were discovered from natural sources, including the majority of antibacterial and anticancer agents.

The cannabinoid technology that forms the basis of MAK Scientific was developed in the laboratory of UConn scientist Alexandros Makriyannis. Using UConn licensed technology, MAK Scientific is in the process of investigating medications for treatment of pain, obesity and glaucoma. The market potential for the company exceeds $9 billion annually in the U.S. for pain therapeutics and $1.2 billion for obesity treatments, their two initial targets. The company's cannbinoid technology will provide favorable alternatives to current products and address unmet needs.

MysticMD™ Inc. is an early stage technology company leveraging specific attributes of carbon nanotube (CNT) based conductive coatings to solve real world problems for the security, medical and performance coatings markets. They employ proprietary, leading edge conductive coating technology for security marking, personal identification and medical/environmental sensor applications. The nCard and Intellimark applications have very broad market appeal. Product and commercialization focused, MysticMD's intellectual property (IP) position includes patent-pending and proprietary technology relating to manufacturing, modification and application of these nanomaterials. MysticMd is currently collaborating with UConn faculty at the Connecticut Global Fuel Cell Center (CGFCC).

New Ortho Polymers, Inc. (“NOP”) is a start-up company launched by UConn R&D Corporation focused on the orthodontics industry based on the Shape Memory Polymer research developed by Dr. Patrick Mather, formerly with the University of Connecticut 's Institute of Materials Science .

New Ortho Polymers is based on a patented shape memory polymer (SMP) technology developed by Dr. Pat Mather at UConn's Institute of Materials Science in Storrs. In cooperation with Dr. Charles Burstone at the UConn School of Dental Medicine, the Company is creating orthodontic appliances that incorporate and utilize shape memory properties for tooth movement. The Company has recently been awarded an STTR grant from the National Institute of Health.

PC Photonics has been developing high-power multi core phase-locked fiber lasers for industrial and military applications. For these applications, high power lasers with good beam quality and short pulses are needed for selective removal or cutting of a variety of materials at high speed, without creating any thermal damage to the surrounding.

VENOMIX is a UConn-based company which exploits the huge pharmacological range of spider venoms to develop natural-product-based insecticides. These are intended to take advantage of major disruptions in world insecticide markets caused by profound changes in governmental regulation of agrochemicals.

Dr. Glenn King, Professor of Molecular, Microbial and Structural Biology at the UConn Health Center and faculty founder of Venomix, researches spider venoms as a source of natural insect toxins. Venomix, using proprietary targets with little or no vertebrate toxicity, develops new insecticidal compounds using high-throughput screening and rational design. These products are targeted at the agricultural, specialty non-crop, and animal health markets, which have a combined market value (for insecticides only) of $15 billion. The Company recently signed a cooperative research agreement with Chemtura Corporation, a $3 billion specialty chemical company. See Press Release and News Article.